drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T)
drug_description
Autologous anti-CD7 chimeric antigen receptor T-cell (CAR-T) therapy; patient T cells are engineered to express a CAR targeting CD7, and upon engagement they activate cytotoxic pathways to eliminate CD7+ malignant T cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor that binds CD7 on T-lineage cells. Upon CD7 engagement, CAR signaling (CD3ζ with costimulatory domains) activates T‑cell cytotoxicity and cytokine release, leading to perforin/granzyme-mediated lysis of CD7+ malignant T-ALL/LL cells, with on‑target depletion of normal CD7+ T (and some NK) cells.
drug_name
CD7-CART01
nct_id_drug_ref
NCT06064903